MBX Biosciences, Inc. (MBX) stock
MBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$55.94+1.43 (+2.62%)
Close on Nov 13, 2026Market cap $2.69BP/E –Yield –
MBX Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
MBX Biosciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $101.27M, up 35.7% year over year. For fiscal 2025 it was $79.16M, up 37.9% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $79.16M | +37.9% |
| FY2024 | Dec 31, 2024 | $57.42M | +101.2% |
| FY2023 | Dec 31, 2023 | $28.53M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $32.05M | +66.3% |
| Q2 FY2026 | Jun 30, 2026 | $30.99M | +74.8% |
| Q1 FY2026 | Mar 31, 2026 | $18.47M | -17.5% |
| Q4 FY2025 | Dec 31, 2025 | $19.76M | +29.8% |
| Q3 FY2025 | Sep 30, 2025 | $19.27M | +15.1% |
| Q2 FY2025 | Jun 30, 2025 | $17.72M | +23.1% |
| Q1 FY2025 | Mar 31, 2025 | $22.41M | +102.8% |
| Q4 FY2024 | Dec 31, 2024 | $15.22M | +97.0% |
| Q3 FY2024 | Sep 30, 2024 | $16.75M | +84.6% |
| Q2 FY2024 | Jun 30, 2024 | $14.40M | – |
| Q1 FY2024 | Mar 31, 2024 | $11.05M | – |
| Q4 FY2023 | Dec 31, 2023 | $7.73M | – |
| Q3 FY2023 | Sep 30, 2023 | $9.07M | – |
See a number that looks wrong?